To understand the significance of the proposal, it helps to recall what mitoxyperilysis actually is. The term describes a recently defined mode of regulated cell death in which the fatal event is the rupture of the plasma membrane, the outer envelope that keeps a cell intact. What distinguishes mitoxyperilysis from other lytic deaths such as pyroptosis or necroptosis is the upstream cause: the membrane fails because mitochondria, the cell’s energy-producing organelles, generate reactive oxygen species that chemically attack nearby membrane lipids. This process, known as lipid peroxidation, degrades the phospholipids that give the membrane its structural integrity. Once enough lipid damage accumulates, the membrane destabilizes and bursts, releasing the cell’s contents. Crucially, the damage is not uniform; it is spatially restricted, concentrated at sites where mitochondria linger close to the plasma membrane. The new review takes that spatial restriction seriously and asks what molecular machinery determines where mitochondria sit in the first place.

The answer proposed by Zhenhong He, Yishu Zhong, Yuhan Luo, Hanyu Li, Yingying Yu and Dingsu Bao centers on mTORC2, one of two large protein complexes built around the mechanistic target of rapamycin kinase. While its sibling complex mTORC1 is famous as a nutrient and growth sensor, mTORC2 is best known for controlling the cytoskeleton, the dynamic scaffold of actin filaments and associated motors that gives cells their shape and drives their movement. mTORC2 promotes the activity of RhoA, a small GTP-binding protein that orchestrates actin remodeling, and supports the formation of lamellipodia, the sheet-like actin protrusions that cells extend when they migrate or reshape their surfaces. According to the framework, when immunometabolic stress keeps mTORC2 switched on for prolonged periods, this cytoskeletal program is disrupted rather than enhanced. Sustained mTORC2 activation suppresses RhoA-dependent cytoskeletal dynamics and lamellipodium formation, leaving the cell’s outer architecture stiff and poorly remodeled.

This suppression has a spatial consequence that lies at the heart of the model. In a healthy, actively remodeling cell, mitochondria are constantly repositioned along cytoskeletal tracks, distributed to wherever energy demand is highest and kept away from regions where their reactive byproducts could do harm. If RhoA-driven dynamics and lamellipodial activity falter, the review argues, mitochondria lose this mobility and form prolonged contacts with the plasma membrane. The organelles effectively become parked against the cell’s outer wall. Because mitochondria continuously generate superoxide and other reactive oxygen species as byproducts of oxidative phosphorylation, any ROS they release at these contact sites accumulates locally rather than being diluted across the cytoplasm. The result is a microenvironment of intense oxidative stress confined to the narrow gap between the mitochondrial outer membrane and the inner face of the plasma membrane, precisely where lipid peroxidation can do the most structural damage.

The chemistry that follows is well characterized in adjacent fields. Reactive oxygen species abstract hydrogen atoms from the unsaturated fatty acid chains of membrane phospholipids, initiating chain reactions of peroxidation that render lipids rigid, fragmented and prone to forming pores. Ferroptosis researchers have shown how extensively lipid peroxidation can compromise membrane integrity when it overwhelms cellular repair systems such as glutathione-dependent peroxidases. The mitoxyperilysis framework borrows this chemistry but adds a crucial geometric constraint: because the peroxidizing ROS are generated at mitochondria held in place near the membrane, the lipid damage is delivered to a specific patch of the plasma membrane rather than arising randomly. Localized peroxidation destabilizes that patch, and once a critical threshold of damage is crossed, the membrane lyses. In this view, cell death is not merely a matter of how much oxidative stress a cell experiences, but of where that stress is delivered, a distinction the authors argue has been underappreciated in the redox cell death literature.

A substantial portion of the review is devoted to positioning mitoxyperilysis against the growing family of redox-associated death modalities. Ferroptosis, the best-studied example, depends on iron-catalyzed lipid peroxidation and can be blocked by lipophilic antioxidants and iron chelators, but its lipid damage is generally considered a cell-wide phenomenon shaped by lipid composition and repair capacity. Pyroptosis and necroptosis rupture the membrane through pore-forming proteins such as gasdermins and MLKL respectively, with oxidative stress playing at most a modulatory role. Mitoxyperilysis, by contrast, is defined by its spatial signature: oxidative membrane damage that is restricted to mitochondrial contact zones. The authors emphasize that this defining feature, spatially restricted oxidative membrane damage, is what sets the modality apart and justifies treating it as a distinct conceptual category rather than a variant of ferroptosis. The comparison also highlights a broader principle emerging in cell death research, namely that subcellular organization, not just molecular identity, shapes how cells die.

The framework also carries implications for disease. Chronic immunometabolic stress, the simultaneous burden of inflammatory signaling and metabolic dysregulation, is a hallmark of conditions ranging from obesity-associated inflammation and atherosclerosis to chronic joint and tissue degeneration. The authors, who work in an orthopedics department and a college of integrated traditional Chinese and Western medicine, suggest that tissues subjected to sustained immunometabolic stress may be prone to mitoxyperilysis-like injury, in which persistently active mTORC2 immobilizes mitochondria near membranes and primes localized oxidative attack. If the model holds, it could help explain patterns of tissue damage that current death classifications do not fully account for, and it points toward therapeutic strategies that are spatially targeted rather than globally suppressive. Inhibiting mTORC2, restoring RhoA-dependent cytoskeletal dynamics, or enhancing mitochondrial mobility might each prevent the fatal apposition of mitochondria and membrane without shutting down mitochondrial metabolism altogether.

It is important to read the review for what it is: a conceptual framework, explicitly framed with cautious language. The authors repeatedly use terms such as may act, could promote and may facilitate, signaling that the causal chain from sustained mTORC2 activation through cytoskeletal suppression to mitochondrial immobilization and localized peroxidation has not yet been demonstrated end to end in living cells. Key experimental tests remain open, including direct imaging of mitochondria-plasma membrane contact duration under mTORC2 hyperactivation, quantitative mapping of lipid peroxidation products at contact sites, and genetic or pharmacological rescue experiments showing that restoring cytoskeletal dynamics prevents lytic death. The work was supported by the Sichuan Provincial Administration of Traditional Chinese Medicine and by a science and technology cooperation program between the Luzhou Municipal People’s Government and Southwest Medical University, and the authors declare no competing interests.

Even as a hypothesis, the framework is likely to resonate because it reframes a familiar molecule in an unfamiliar role. mTORC2 has long been studied as a signaling hub for growth, survival and cytoskeletal organization, and mTOR inhibitors are staples of cancer and immunology research. The idea that the same complex could function as a spatial regulator of cell death, effectively deciding where a cell’s own mitochondria are allowed to sit, adds a geometric dimension to signaling biology that few models have attempted. It also joins a broader movement in cell biology that treats the position of organelles as information in its own right, as important as their enzymatic activity. If subsequent experiments confirm the mTORC2-cytoskeleton-mitochondrial positioning axis, mitoxyperilysis could become a textbook example of how subcellular architecture converts metabolic stress into a precisely located lethal blow, and the search for spatially targeted therapies in immunometabolic disease would gain a concrete molecular starting point.

Subject of Research: An mTORC2-driven mitochondrial positioning framework links immunometabolic stress to spatially restricted oxidative membrane damage in mitoxyperilysis

Article Title: An mTORC2-driven mitochondrial positioning framework links immunometabolic stress to spatially restricted oxidative membrane damage in mitoxyperilysis

Article References: He, Z., Zhong, Y., Luo, Y., Li, H., Yu, Y., & Bao, D. (2026). An mTORC2-driven mitochondrial positioning framework links immunometabolic stress to spatially restricted oxidative membrane damage in mitoxyperilysis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03362-x

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03362-x

Keywords: mTORC2-driven, mitochondrial, positioning, framework, links, immunometabolic, stress, spatially, restricted, oxidative, membrane, damage

The clinical starting point was a group of patients whose stomachs suffer as a consequence of their livers. The team enrolled 111 patients with hepatitis B-related liver cirrhosis or hepatic failure at the Third Affiliated Hospital of Sun Yat-sen University between January 2022 and August 2024, alongside 118 control subjects. Using the gastrointestinal symptom rating scale, a validated 15-item questionnaire, the researchers found that patients with liver disease scored significantly higher overall than controls, 51.49 versus 42.40, with heartburn, acid reflux, nausea, bloating and diarrhea all markedly more frequent. Endoscopy told a matching story: the diseased mucosa showed more erosion and bleeding, and statistical analysis confirmed that mucosal lesions correlated with higher symptom scores, while normal mucosa tracked with lower scores.

Why would a congested stomach become a hypoxic one? The explanation is vascular. In portal hypertension and hepatic failure, restricted blood flow through the portal vein causes gastric venous congestion, and the oxygen supply to the epithelium falls behind demand. Using Hypoxyprobe-1 staining, the team demonstrated that hypoxia was indeed present in the gastric epithelium of these patients. In parallel, they established a mouse model of portal hypertension by partially ligating the portal vein, and again the hypoxia signal rose in step with a quantified gastric injury index. Crucially, the transcription factor HIF-1α, the master regulator of the cellular response to low oxygen, accumulated in the nuclei of epithelial cells in both human and mouse tissue, poised to reprogram gene expression.

That reprogramming showed up first as a metabolic shift. RNA sequencing of clinical gastric samples revealed enrichment of glycolysis and anaerobic metabolism pathways, and untargeted metabolomics of epithelial cells from the mouse model confirmed the biochemical signature: lactic acid rose while isocitric acid and citric acid, intermediates of the mitochondrial citric acid cycle, fell. This is the classic Warburg-like pattern in which cells, deprived of the oxygen needed for oxidative phosphorylation, burn glucose to lactate instead. In the short term this is a survival strategy, but the study suggests that under sustained hypoxia it becomes pathological, feeding a vicious cycle of metabolic disorder, reactive oxygen species generation and cell death.

The central molecular discovery concerns FUNDC1, an outer mitochondrial membrane protein previously known to help build mitochondria-associated ER membranes, or MAMs. These contact sites are far more than structural curiosities: they regulate calcium transfer from the ER to mitochondria, lipid exchange and mitochondrial dynamics. The researchers found that HIF-1α binds directly to a hypoxia-responsive element in the FUNDC1 promoter, driving its transcription, and that a second, post-transcriptional layer reinforces this. The m6A methyltransferase METTL3 chemically modified FUNDC1 messenger RNA, and the RNA-binding protein IGF2BP3, the most upregulated m6A reader in cirrhotic gastric tissue, recognized and stabilized that modified transcript. In mice carrying a mutant METTL3, FUNDC1 upregulation was blunted, confirming the epitranscriptomic mechanism.

With FUNDC1 elevated, the ER and mitochondria embraced more tightly. Transmission electron microscopy showed expanded contact zones in epithelial cells from portal hypertensive mice and from cirrhotic patients, and a proximity ligation assay for the IP3R2–VDAC1 tethering pair quantified the same increase. Coimmunoprecipitation confirmed that FUNDC1, IP3R2, VDAC1 and GRP75 formed complexes under hypoxic conditions. Truncation experiments pinpointed amino acids 7 to 48 of FUNDC1 as the domain essential for MAMs formation, a detail the authors highlight as a blueprint for designing inhibitors that could block the tethering interface specifically.

The consequences of this hyper-tethering were metabolic and oxidative. Seahorse extracellular flux analysis showed that epithelial cells under hypoxia had reduced maximal respiration, increased proton leak, elevated non-mitochondrial oxygen consumption and heightened basal and compensatory glycolysis, all of which were reversed when FUNDC1 was knocked down. Levels of electron transport chain subunits NDUFA9, SDHA, cytochrome b and ATP5A fell, along with ATP production. Meanwhile, mitochondrial superoxide, lipid peroxidation products such as 4-HNE and malondialdehyde, and oxidized mitochondrial DNA all climbed, while antioxidant defenses, superoxide dismutase activity and the glutathione redox ratio, collapsed. Calcium handling was also disturbed, with both cytosolic and mitochondrial calcium rising and membrane potential falling.

The final executioner in the cascade was NINJ1, a transmembrane protein that has recently emerged as the mediator of plasma membrane rupture during lytic cell death. In its inactive state NINJ1 is scattered across the membrane; when activated it oligomerizes into polymers that lyse the membrane and spill cellular contents. The team found NINJ1 oligomerization increased in gastric tissue from cirrhotic and hepatic failure patients, alongside elevated cleaved caspase-3 and cleaved caspase-1, markers of apoptosis and pyroptosis. Silencing NINJ1 in mice with portal hypertension reduced lactate dehydrogenase release, a readout of membrane permeabilization, restored epithelial viability and lessened mucosal injury. Notably, NINJ1 blockade did not change caspase activation, indicating it acts at the terminal step of membrane rupture rather than upstream of cell death signaling.

Two intervention experiments tied the whole axis together and pointed toward the clinic. Mito-TEMPO, a mitochondria-targeted antioxidant, suppressed NINJ1 oligomerization, reduced LDH release and protected the gastric mucosa in the mouse model, placing mitochondrial reactive oxygen species upstream of NINJ1 activation. The HIF-1α inhibitor PX-478 suppressed FUNDC1 expression and attenuated injury. Confocal imaging also showed that fragmented mitochondrial DNA released under oxidative stress colocalized with NINJ1, hinting at a direct or indirect role for escaping mtDNA in activating the rupture machinery, though the authors acknowledge the precise mechanism remains unresolved.

The authors are candid about limitations. The partial portal vein ligation model mechanically constricts the portal vein without reproducing hepatic parenchymal injury, systemic inflammation or the other comorbidities of clinical cirrhosis, and only knockdown rather than tissue-specific knockout approaches were used. Yet the reversibility of the pathway is encouraging: because MAMs remodeling is dynamic rather than covalent, targeted disruption of excessive ER-mitochondria tethering, inhibition of METTL3 or IGF2BP3 with emerging small molecules, or blockade of NINJ1 oligomerization with monoclonal antibodies could, in principle, interrupt the cycle before irreversible tissue damage sets in. If those strategies survive preclinical and clinical testing, the humble contact points between two organelles may become the address at which doctors finally treat the stomach’s silent suffocation.

Subject of Research: The FUNDC1–MAMs–NINJ1 signaling axis in hypoxia-induced gastric mucosal injury

Article Title: Mitochondria-associated endoplasmic reticulum membranes facilitate gastric epithelial injury in hypoxia-induced gastric mucosal lesions

Article References: Tan, S., Luo, J., Ou, X., Guo, X., Ke, B., & Tan, S. (2026). Mitochondria-associated endoplasmic reticulum membranes facilitate gastric epithelial injury in hypoxia-induced gastric mucosal lesions. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.007

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.007

Keywords: hypoxia, gastric mucosal injury, mitochondria-associated ER membranes, FUNDC1, HIF-1α, m6A methylation, METTL3, IGF2BP3, NINJ1, portal hypertension, mitochondrial oxidative stress, plasma membrane rupture

NINJ1 first attracted attention in immunology circles for its unusual structural capabilities. When activated during lytic forms of cell death, including pyroptosis and necroptosis, NINJ1 proteins assemble into filamentous oligomers along the cell surface. Using a distinctive helical-alpha helix interaction motif, these proteins pack side by side into a growing chain that ultimately seals into a ring, mechanically prying the membrane apart. Cryo-electron microscopy studies have revealed how individual subunits engage one another and how small molecules can disrupt this assembly, offering researchers their first mechanistic picture of how a cell actively tears itself open. The result is the release of intracellular contents, ranging from damage-associated molecular patterns such as HMGB1 and ATP to mature inflammatory cytokines, into the extracellular space, where they act as powerful alarm signals for the immune system.

The scope of NINJ1’s involvement, however, extends well beyond pyroptosis. The review systematically traces the protein’s fingerprints across the major lytic death pathways. In necroptosis, driven by the MLKL kinase downstream of TNF receptor signaling, NINJ1 determines whether membrane breakdown is complete and whether cellular contents spill out to provoke inflammation. In ferroptosis, the iron-dependent lipid peroxidation-driven death implicated in tissue injury and therapy resistance, NINJ1 likewise mediates the terminal rupture. Even in secondary necrosis, the late-stage membrane collapse that follows otherwise non-lytic apoptosis, NINJ1 appears to govern the release of material from cells that initially died quietly. In PANoptosis, a recently described inflammatory death modality that integrates features of pyroptosis, apoptosis, and necroptosis, NINJ1 sits at the convergence point where intracellular alarm systems are converted into extracellular immunological signals.

This role in content release has profound consequences for inflammation. The magnitude and character of the immune response triggered by a dying cell depend substantially on what escapes through the ruptured membrane and in what quantity. By controlling plasma membrane rupture, NINJ1 effectively acts as a rheostat for the inflammatory tone of a tissue. In settings of acute infection, this can be protective, amplifying the recruitment of neutrophils and macrophages to sites of microbial invasion. In chronic disease, however, the same mechanism can sustain a self-perpetuating cycle of damage and inflammation, a dynamic well recognized in sepsis, ischemia-reperfusion injury, and inflammatory bowel disease. Pharmacological interference with NINJ1 oligomerization, informed by recent structural work, is now being explored as a strategy to dampen pathological inflammation without abolishing cell death itself.

It is in cancer, though, that NINJ1’s story becomes genuinely double-edged, and it is this duality that forms the conceptual core of the review. On one side of the ledger, NINJ1 can function as a tumor suppressor. When cancer cells undergo immunogenic cell death, the release of tumor antigens and danger signals through NINJ1-mediated rupture can provoke a robust adaptive immune response, generating dendritic cell activation, T cell priming, and durable anti-tumor immunity. In this context, a cell that dies loudly and publicly is a cell that teaches the immune system to recognize and eliminate its malignant relatives. Chemotherapy and radiotherapy regimens that induce immunogenic death may therefore depend partly on intact NINJ1 function for their full therapeutic benefit, raising the possibility that NINJ1 status could serve as a biomarker for treatment response.

On the other side of the ledger, the review documents compelling evidence that NINJ1 can act as a pro-tumor factor. In the tumor microenvironment, chronic and poorly resolved inflammatory death can fuel the very processes that cancers exploit to progress. Persistent release of inflammatory mediators promotes the recruitment of immunosuppressive myeloid cells, skews macrophages toward tumor-promoting phenotypes, and creates a milieu favorable to angiogenesis and invasion. Moreover, tumor cells with altered NINJ1 expression may evade immune recognition or reshape their surroundings in ways that facilitate metastasis. The review also highlights the p53–NINJ1–xCT axis as an instructive example of context-dependent regulation, in which the tumor suppressor p53 influences NINJ1 expression and, through it, the activity of the cystine-glutamate antiporter xCT, linking cell death execution directly to metabolic adaptation and ferroptosis sensitivity in cancer cells.

Immune cell trafficking adds yet another layer to NINJ1’s expanding portfolio. The protein takes its name from the Japanese word ninjin, meaning nerve, reflecting its original identification in neuronal adhesion, and earlier work established roles for ninjurins in leukocyte migration and adhesion. In tumors, immune cell infiltration is a critical determinant of prognosis and immunotherapy success, and NINJ1-dependent mechanisms appear to influence how immune cells move through and interact with the tumor stroma. The review suggests that dissecting these functions could reveal why some tumors mount vigorous immune infiltrates while others remain immunologically cold, a distinction with direct implications for checkpoint inhibitor therapy.

From a translational standpoint, the authors frame NINJ1 as a molecule whose therapeutic manipulation must be exquisitely context-aware. Blocking NINJ1 might relieve destructive inflammation in sepsis or autoinflammatory disease, yet the same intervention could blunt the immunogenic death signals that make certain anti-cancer treatments work. Conversely, enhancing NINJ1-mediated rupture within tumors might convert immunologically silent lesions into inflamed, immune-visible targets, but it risks amplifying the chronic inflammatory circuits that drive tumor progression in other settings. The dual role means that NINJ1-directed therapies will likely require careful patient selection, perhaps guided by tumor genotype, p53 status, and the inflammatory signature of the microenvironment. Structural insights into the oligomerization interface provide a concrete starting point for the development of small-molecule modulators that could tip this balance in either direction.

What emerges from this synthesis is a portrait of cell death as a finely engineered process whose final mechanical step carries as much biological meaning as the genetic programs that trigger it. NINJ1, once a footnote in the cell death literature, now stands at the intersection of structural biology, immunology, and oncology, a protein that decides how loudly a dying cell announces its demise and whether that announcement heals or harms. As clinical trials of cell death modulators advance and structural biology continues to refine our understanding of the NINJ1 filament, the coming years may determine whether this membrane rupture executor can be harnessed as a versatile tool, quieting catastrophic inflammation on one hand and igniting anti-tumor immunity on the other. For a molecule that works by tearing membranes apart, NINJ1 is proving remarkably adept at knitting together previously separate fields of biomedical research.

Subject of Research: The role of the NINJ1 protein in plasma membrane rupture during regulated cell death and its dual functions in cancer progression

Article Title: NINJ1 in regulated cell death and cancer: a plasma membrane rupture executor with dual roles in tumor progression

Article References: Zhou, J., Li, M., Tan, S., & Tan, S. (2026). NINJ1 in regulated cell death and cancer: a plasma membrane rupture executor with dual roles in tumor progression. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06592-9

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06592-9

Keywords: NINJ1, plasma membrane rupture, regulated cell death, pyroptosis, necroptosis, ferroptosis, PANoptosis, immunogenic cell death, tumor microenvironment, p53–NINJ1–xCT axis, cancer therapy, inflammation